Compare GROW & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROW | TELA |
|---|---|---|
| Founded | 1968 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 36.7M |
| IPO Year | N/A | 2019 |
| Metric | GROW | TELA |
|---|---|---|
| Price | $3.25 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | 129.8K | ★ 329.4K |
| Earning Date | 11-13-2025 | 03-19-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | $8,546,000.00 | ★ $77,055,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | $49.99 | ★ N/A |
| Revenue Growth | N/A | ★ 12.24 |
| 52 Week Low | $2.02 | $0.68 |
| 52 Week High | $3.65 | $2.96 |
| Indicator | GROW | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 32.54 |
| Support Level | $2.88 | $0.76 |
| Resistance Level | $3.33 | $0.86 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 48.05 | 20.69 |
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.